1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

More Surufatinib Cheer For Chi-Med As Second NET Trial Stopped Early

Multi-Modal Candidate Meets Endpoint In Pancreatic Setting

 
• By Ian Haydock

Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.

Competitive edge and business advantage concept as a group of hot air balloons racing to the top but an individualleader with a small balloon attached giving the winning competitor an extra boost.
New Results Buoy Chi-Med • Source: Shutterstock

Hutchison China MediTech Ltd. (Chi-Med) has further strengthened its position for its first planned independent launch in China, after a second trial with anticancer surufatinib was stopped early after meeting its pre-defined primary endpoint of progression free survival (PFS).

The independent data monitoring committee of the Phase III SANET-p pivotal study in patients with advanced pancreatic neuroendocrine tumors (NET) recommended that the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas